New HIV prevention pill trial aims to stop infections before they start

NCT ID NCT02842086

Ongoing Prevention Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

Summary

This large study tested whether a daily pill containing two drugs (F/TAF) is safe and effective at preventing HIV infection. It involved over 5,300 men and transgender women who have sex with men and are at high risk of getting HIV. The study compared this new pill to an older, similar pill (F/TDF) to see which one better prevents infection and has fewer side effects on bones and kidneys.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-EXPOSURE PROPHYLAXIS OF HIV-1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Study site

Beverly Hills, California, 90211, United States
Study site

Los Angeles, California, 90036, United States
Study site

Los Angeles, California, 90069, United States
Study site

Newport Beach, California, 92663, United States
Study site

Oakland, California, 94609, United States
Study site

Sacramento, California, 95817, United States
Study site

Sacramento, California, 95825, United States
Study site

San Diego, California, 92103, United States
Study site

San Francisco, California, 94102, United States
Study site

San Francisco, California, 94103, United States
Study site

San Francisco, California, 94118, United States
Study site

Torrance, California, 90502, United States
Study site

Aurora, Colorado, 80045, United States
Study site

Denver, Colorado, 80209, United States
Study site

New Haven, Connecticut, 06510, United States
Study site

Washington D.C., District of Columbia, 20009, United States
Study site

Washington D.C., District of Columbia, 20036, United States
Study site

Fort Lauderdale, Florida, 33308, United States
Study site

Fort Lauderdale, Florida, 33316, United States
Study site

Ft. Pierce, Florida, 34982, United States
Study site

Miami, Florida, 33136, United States
Study site

Orlando, Florida, 32803, United States
Study site

Pensacola, Florida, 32504, United States
Study site

West Palm Beach, Florida, 33407, United States
Study site

Atlanta, Georgia, 30308, United States
Study site

Atlanta, Georgia, 30309, United States
Study site

Atlanta, Georgia, 30312, United States
Study site

Macon, Georgia, 31201, United States
Study site

Chicago, Illinois, 60612, United States
Study site

Chicago, Illinois, 60613, United States
Study site

New Orleans, Louisiana, 70119, United States
Study site

Boston, Massachusetts, 02215, United States
Study site

Springfield, Massachusetts, 01105, United States
Study site

Berkley, Michigan, 48072, United States
Study site

Detroit, Michigan, 48202, United States
Study site

Minneapolis, Minnesota, 55415, United States
Study site

Las Vegas, Nevada, 89104, United States
Study site

Somers Point, New Jersey, 08244, United States
Study site

Santa Fe, New Mexico, 87505, United States
Study site

New York, New York, 10029, United States
Study site

New York, New York, 10032, United States
Study site

New York, New York, 10037, United States
Study site

The Bronx, New York, 10467, United States
Study site

Chapel Hill, North Carolina, 27599-7215, United States
Study site

Huntersville, North Carolina, 28078, United States
Study site

Cleveland, Ohio, 44109, United States
Study site

Philadelphia, Pennsylvania, 19107, United States
Study site

Austin, Texas, 78705, United States
Study site

Dallas, Texas, 75208, United States
Study site

Dallas, Texas, 75246, United States
Study site

Houston, Texas, 77098, United States
Study site

Seattle, Washington, 98101, United States
Study site

Seattle, Washington, 98104, United States
Study site

Milwaukee, Wisconsin, 53226, United States
Study site

Graz, 8051, Austria
Study site

Vienna, 1090, Austria
Study site

Vancouver, British Columbia, V6Z 2T1, Canada
Study site

Toronto, Ontario, M5G 1K2, Canada
Study site

Montreal, Quebec, H2l 4P9, Canada
Study site

Montreal, Quebec, H2L5B1, Canada
Study site

Montreal, Quebec, H2W 1T8, Canada
Study site

Hvidovre, Capital Region, 2650, Denmark
Study site

Aarhus N, Central Jutland, 8200, Denmark
Study site

Copenhagen, RegionH, 2100, Denmark
Study site

Odense, 5000, Denmark
Study site

Nice, Alpe Maritimes, 6202, France
Study site

Marseille, Provence-Alpes-Côte d'Azur Region, 13006, France
Study site

Paris, Provence-Alpes-Côte d'Azur Region, 75020, France
Study site

Paris, 75475, France
Study site

Munich, Bavaria, 81675, Germany
Study site

Berlin, 10439, Germany
Study site

Berlin, 10777, Germany
Study site

Frankfurt, 60596, Germany
Study site

Dublin, Dublin, D07 A8NN, Ireland
Study site

Dublin, 8, Ireland
Study site

Milan, 20127, Italy
Study site

Roma, 00149, Italy
Study site

Amsterdam, Netherlands
Study site

Badalona, Barcelona, 08907, Spain
Study site

Barcelona, 08015, Spain
Study site

Madrid, 28010, Spain
Study site

Vigo, 36312, Spain
Study site

Soho, London, W1D 6AQ, United Kingdom
Study site

Whitechapel, London, E1 1BB, United Kingdom
Study site

Edinburgh, Scotland, EH3 9HA, United Kingdom
Study site

Brighton, Sussex, BN2 1ES, United Kingdom
Study site

Birmingham, B9 5SS, United Kingdom
Study site

London, E9 6SR, United Kingdom
Study site

London, SE18 4QH, United Kingdom
Study site

London, SE5 9RJ, United Kingdom
Study site

London, W2 1NY, United Kingdom
Study site

London, WC1E 6JB, United Kingdom
Study site

Manchester, M13 0FH, United Kingdom

Conditions

Explore the condition pages connected to this study.

PRE-EXPOSURE PROPHYLAXIS OF HIV-1 INFECTION